CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-20 | Alam Kamran Chief Financial Officer | Sale | −9,746 | $16.70 | $163K | 300,215 |
| 2021-08-20 | Alam Kamran Chief Financial Officer | Sale | −2,094 | $17.14 | $36K | 298,121 |
| 2021-08-19 | Alam Kamran Chief Financial Officer | Sale | −9,354 | $16.43 | $154K | 310,574 |
| 2021-08-19 | Alam Kamran Chief Financial Officer | Sale | −613 | $17.11 | $10K | 309,961 |
| 2021-08-18 | Alam Kamran Chief Financial Officer | Sale | −11,193 | $17.35 | $194K | 319,928 |
| 2021-07-01 | PRASAD SUYASH CMO and Head of R&D | Sale | −19,706 | $21.12 | $416K | 593,589 |
| 2021-06-30 | PRASAD SUYASH CMO and Head of R&D | Sale | −13,374 | $21.42 | $286K | 619,997 |
| 2021-06-30 | PRASAD SUYASH CMO and Head of R&D | Sale | −6,202 | $22.44 | $139K | 613,795 |
| 2021-06-30 | PRASAD SUYASH CMO and Head of R&D | Sale | −500 | $23.70 | $12K | 613,295 |
| 2021-06-29 | PRASAD SUYASH CMO and Head of R&D | Sale | −35,056 | $23.74 | $832K | 637,533 |
| 2021-06-29 | PRASAD SUYASH CMO and Head of R&D | Sale | −3,862 | $24.46 | $94K | 633,671 |
| 2021-06-29 | PRASAD SUYASH CMO and Head of R&D | Sale | −300 | $25.19 | $8K | 633,371 |
| 2021-06-17 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Nagendran Sukumar Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Nolan Sean P. Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Reape Kathleen Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Sepp-Lorenzino Laura Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-06-17 | Manning Paul B Director | Grant or award · Stock Option (right to buy) | +15,500 | 15,500 | ||
| 2021-05-20 | Nolan Sean P. Director | Purchase | +1,170 | $22.35 | $26K | 1,170 |
| 2021-05-14 | Manning Paul B Director | Purchase | +12,000 | $20.98 | $252K | 12,000 |
Page 8 of 9 · 173 trades